Structures of langya virus fusion protein ectodomain and immunogenic compositions derived therefrom
US-2024358817-A1 · Oct 31, 2024 · US
US10247734B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10247734-B2 |
| Application number | US-201515123138-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2015 |
| Priority date | Mar 4, 2014 |
| Publication date | Apr 2, 2019 |
| Grant date | Apr 2, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Multimenic lectins having a β-propeller architecture, formed from monomer modules of approximately 30 to 60 amino acids, in which the binding sites to the glycans are situated on a given side of the proteins and the O-terminus and N-terminus ends of the peptide chains on the other side of the proteins, characterized in that they are formed from 4 to 7 monomer modules, a single, or a plurality of, or all of the adjacent modules being linked to one another by the linkers linking the N-terminus end of one module to the C-terminus end of the adjacent module.
Opening claim text (preview).
The invention claimed is: 1. A monomeric, single polypeptide chain lectin having a β-propeller architecture, said lectin comprising 4 to 7 peptide modules, wherein each module comprises about 30 to 60 amino acids; wherein each module comprises a glycan binding site; wherein at least one glycan binding site comprises at least one mutation, said mutation altering glycan binding; wherein each module is linked to another module with a peptide linker; and wherein at least one peptide linker is an exogenous peptide linker. 2. The lectin of claim 1 , wherein the peptide linkers are the same or different, wherein the peptide linkers comprises 2 to 10 amino acids. 3. The lectin of claim 1 , wherein the lectin is multivalent and capable of binding more than one glycan or the lectin is monovalent and binds a single glycan. 4. The lectin of claim 1 , wherein the lectins comprises one or more lysine functional groups, wherein the lysine functional groups comprise a label. 5. The lectin of claim 4 , wherein said label is a fluorophore or biotin. 6. The lectin of claim 1 , wherein the peptide modules are derived from RSL ( Ralstonia solanacearum lectin), BambBL ( Burkholderia ambifaria lectin), BC2LL-nt ( Burkholderia cenocepacia lectin), HPA ( Helix pomatia lectin), discoidin ( Dictyostelium discoideum lectin), CTX-B (cholera toxin lectin) lectins, B5 type bacterial toxins, AAA ( Anguilla anguilla lectin), and adenovirus lectin. 7. A method for producing the monomeric, single polypeptide chain lectin of claim 1 , said method comprising: transforming a host cell with nucleic acid encoding the monomeric, single chain lectin, culturing said host cell in culture medium under conditions for the expression of the monomeric, single polypeptide chain lectin, isolating the monomeric, single polypeptide chain lectin from the host cells or the culture medium. 8. A method for identifying glycosylation epitopes on a cell surface in vitro, said method comprising: contacting cells with the lectin of claim 1 , wherein the glycosylation epitopes are identified when the lectin binds to the cell surface glycan.
for HIV · CPC title
Antivirals · CPC title
Lectins · CPC title
involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title
Lectins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.